🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — November 2025 Page 3

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — November 2025

LabKate Sat, Mar 14, 2026 at 9:46 PM 36 replies 1,552 viewsPage 3 of 8
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Mar 15, 2026 at 3:39 PM#11
anders_CPH said:
The dose-response is real but shallow at the top.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

6 4JakeSmashed95, NauseaFreeNow, SteveThurs and 3 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Mar 16, 2026 at 3:52 AM#12
KristenIndy said:
True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of…

Saving this. It is the first explanation that did not require me to already understand it. Sending this to two other people who asked me the same thing last week.

Last edited: Mar 16, 2026 at 9:52 AM
7 5ricardo_MIA, BrianDallas92, labquiet_amy and 4 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Mar 16, 2026 at 4:05 PM#13
anders_CPH said:
The dose-response is real but shallow at the top.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

8 6tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 5 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Mar 17, 2026 at 4:17 AM#14

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Correct me if the detail matters more than I have assumed.

Last edited: Mar 17, 2026 at 5:17 AM
9 7cory_ATX, lori_vegas, Dr.PulmRoch and 6 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Mar 17, 2026 at 4:29 PM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Tagging this one for the weekly digest.

10 8PurityPaulOR, MaxMetOK, MounjBrad and 7 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register